BME100 f2013:W900 Group6 L2

BME 100 Fall 2013	Home People Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3 Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6 Course Logistics For Instructors Photos Wiki Editing Help
OUR TEAM Name: Areli Isherwood Role(s) Name: Jacob Hulett Role(s) Name: James Mendoza Role(s) Name: Brandon Kehring Role(s) Name: Courtney DuBois Role(s) Name: student Role(s) LAB 2 WRITE-UP Descriptive Statistics Experiment 1 (Human) ' Treatment - Human Study ' ' ' Inflammotin (pg/ml) LPS Dose (mg) 0mg 5mg 10mg 15mg 5.23 10.72 100.19 793.17 1.01 9.29 75.92 476.67 4.23 8.46 23.46 771.45 1.87 10.19 70.87 795.09 3.67 7.29 19.27 181.27 2.98 7.54 99.65 752.78 5.83 8.67 38.37 934.23 5.24 6.15 76.26 554.87 4.27 10.92 35.25 692.23 4.01 10.09 76.98 627.65 Average 3.834 8.932 61.622 657.941 Standard Deviation 1.523010177 1.593931547 30.11069386 212.9429762 Endpoint # 10 10 10 10 Standard Error 0.481618106 0.504045412 9.521837451 67.33848166 Experiment 2 (Rat) ' Treatment - Rat Study ' Inflammotin (pg/ml) LPS Dose (mg) 0mg 10mg 9.24 22.34 8.76 6.45 8.78 14.23 13.5 3.55 12.3 8.99 Average 10.516 11.112 Standard Deviation 2.225551617 7.402885924 Endpoint # 5 5 Standard Error 0.995296941 3.310671231 Results Experiment 1 (Human) Experiment 2 (Rat) Analysis Experiment 1 (Human) Analysis of Variance (One-Way) ' ' ' ' ' ' Summary Groups Sample size Sum Mean Variance 0mg 10 38.34 3.834 2.31956 5mg 10 89.32 8.932 2.54062 10mg 10 616.22 61.622 906.65388 15mg 10 6,579.41 657.941 45,344.71112 ANOVA Source of Variation SS df MS F p-level F crit Between Groups 3,027,016.69485 3 1,009,005.56495 87.2536 1.11022E-16 3.71396 Within Groups 416,306.02665 36 11,564.0563 Total 3,443,322.7215 39 Bonferroni Correction ' ' ' Post-hoc Tests T-Test Value Corrected p-value to achieve significance Significant? 0 mg vs 5 mg 8.59631E-07 0.00833 Yes 0 mg vs 10 mg 9.94377E-06 0.00833 Yes 0 mg vs 15 mg 1.39436E-08 0.00833 Yes 5 mg vs 10 mg 3.01859E-05 0.00833 Yes 5 mg vs 15 mg 1.57101E-08 0.00833 Yes 10 mg vs 15 mg 6.4824E-08 0.00833 Yes Experiment 2 (Rat) T-Test assuming equal variances ' ' ' Descriptive Statistics VAR Sample size Mean Variance 5 10.516 4.95308 5 11.112 54.80272 Summary Degrees Of Freedom 8 Hypothesized Mean Difference 0.E+0 Test Statistics 0.1724 Pooled Variance 29.8779 Two-tailed distribution p-level 0.8674 t Critical Value (5%) 2.306 Corrected p-value to achieve significance Significant? 0.025 No Summary/Discussion The intention of our study was to validate whether or not LPS had a significant effect on the inflammation protein Inflammotin. Two experiments where conducted: one experiments used rats as a testing group, while another experiment used humans as a testing group. Experiment 1 (humans): In this experiment, LPS was given to humans in increments of 0mg, 5mg, 10mg, and 15mg. We noticed that there was an exponential increased in LPS and protein levels. As the dosage of LPS increased, the protein level of the test subjects also increased (particularly between the dosages of 10mg and 15mg of LPS). After gathering data and performing an ANOVA test followed by a Bonferroni Correction, we discovered that all of our results are statistically significant as all treatment groups had a p-value less than 0.05. Because each value has statistical significance, our lab group concluded that the increase in human protein levels is directly related to an increase in dosage of LPS. Experiment 2 (rats): When testing rats with LPS dosages of 0mg and 10mg, our data indicated that there was a minor increase in protein levels and LPS dosage. However, we performed a t-test and upon further inspection discovered that the information gathered is not statistically significant as the p-value is greater than 0.05. From this information, our group concluded that the LPS drug did not have a correlation with the protein levels of rats.